undamentalytics Newsletter
Sign in

Altimmune, Inc. cash flow statement

In fiscal 2025, Altimmune, Inc.'s operations generated −$67.5m of cash; it spent $11,000 on capital projects, leaving free cash flow of −$67.5m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2010Dec 20102011Dec 20112016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025
Cash from operations−15−8−6−20−9−10−34−78−63−76−80−68
Depreciation and amortisation10000001−0000
Stock-based pay331111368111416
Capital spending00001001200—0
Free cash flow−15−8−6−20−10−10−35−90−63−76—−68
Free cash flow after stock pay−18−10−7−22−11−11−37−96−71−86—−84
Shares issued—64—4—4865568710174

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: ALT vs LYELAIM vs ALTALT vs IBIO

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Altimmune, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Altimmune, Inc.